Article
Eribulin Binds at Microtubule Ends to a Single Site on Tubulin To Suppress Dynamic Instability
23 Dec 2009
Abstract excerpt
Eribulin mesylate (E7389), a synthetic analogue of the marine natural product halichondrin B, is in phase III clinical trials for the treatment of cancer. Eribulin targets microtubules, suppressing dynamic instability at microtubule plus ends through an inhibition of microtubule growth with little or no effect on shortening [Jordan, M. A., et al. (2005) Mol. Cancer Ther. 4, 1086-1095]. Using [(3)H]eribulin, we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
